The deficiency of αβ TCR abolished the GVHD reaction, and the knockout of CD52 rendered the CAR-T cell resistant to alemtuzumab (an anti-CD52 monoclonal antibody that is used to eliminate host T cells). The gene discussed is CD52; the disease is graft versus host disease.